The oxytocin market is expected to record a CAGR of 5.4% over the forecast period.
COVID-19 significantly impacted the oxytocin market and the overall healthcare industry during the initial phase. For instance, as per the article published in May 2022 under the title "Oxytocin, the Panacea for Long-COVID? A Review", in the study," researchers evaluated the underlying mechanisms for long-COVID and how the oxytocinergic neurons are likely to be affected by SARS-CoV-2 leading to a reduction in plasma oxytocin (OXT). The study also identified a potential mechanism for long-COVID that involves OXT dysfunction. Furthermore, the article published in August 2021 titled" Covid and Oxytocin: Looking for Microbial Symbiosis” stated that the oxytocin hormone has anti-inflammatory and antioxidant protective effects and has received particular attention due to the pandemic of COVID-19. Hence, as per the factors mentioned above, COVID-19 significantly impacted the oxytocin market.
Factors driving the market growth include the increasing prevalence of pregnancy complications, rising births globally, and growing awareness of induced labor and breastfeeding. For instance, as per the December 2021 update from United Nations International Children's Emergency Fund (UNICEF), an estimated 140 million children were born in 2021. Furthermore, as per the August 2021 update from International Institute for Sustainable Development, the global population is projected to increase to 9.7 billion by 2050. This level represents a nearly 24% increase over 2020. Because of the increased birth rate and population levels, there is a high chance for growth of the oxytocin market since oxytocin is advised for antepartum and postpartum pregnancy.
Moreover, the presence of competitors, new developments associated with oxytocin, and collaborations boost the market growth. For instance, per the January 2021 update, Tonix Pharmaceuticals entered a licensing agreement with Katana Pharmaceuticals for its intranasal potentiated oxytocin to expand its use in metabolic disorders, especially insulin resistance, diabetes, and obesity. The licensing deal is an addition to the company's original purchase of oxytocin-potentiated therapy from Trigemina in June 2020, with preclinical data demonstrating the efficacy of the intranasal oxytocin product TNX-1900 in disorders of the central nervous system, with migraine chosen as the lead indication by Tonix. These oxytocin-related collaborative ventures and partnerships open the way for various indications, supporting the market's growth over the forecast period.
Furthermore, the application of oxytocin in pregnancy boosts the market growth, for instance, as per the article published in July 2020 titled "Role of Oxytocin in Prevention of Postpartum Hemorrhage in Unplanned Out-of-Hospital Deliveries Treated By Emergency Medical Services" in Finland, postpartum hemorrhage following unplanned out-of-hospital deliveries was prevented by intramuscular or intravenous oxytocin administration. Rising disposable incomes, especially in developing countries, increasing awareness regarding pregnancy care products among women, an increase in the literacy rate of women, and an increase in well-developed distribution channels for oxytocin products are the major factors driving the growth of the oxytocin market.
As per the factors above, the oxytocin market will likely grow over the forecast period. However, stringent regulations and the high cost of oxytocin drugs associated with the drug restrain the market growth.
Research and development, product launches, mergers, and acquisitions in the studied segment boost the market growth. For instance, as per the article published in May 2020 under the title “Augmentation of Labor With Oxytocin and its Association With Delivery Outcomes: A Large-Scale Cohort Study in 12 Public Hospitals in Nepal”, the augmentation of labor with oxytocin was associated with beneficial effects, such as improved monitoring and a decreased risk of cesarean section. Proper use of oxytocin was needed to augment labor in low-resource contexts and call for evidence-based guidelines on the augmentation of labor in low-resource settings.
Moreover, according to the article titled “The Role of Oxytocin and the Effect of Stress During Childbirth: Neurobiological Basics and Implications for Mother and Child,” published in October 2021 stated that, during pregnancy, childbirth, and beyond, the neuropeptide oxytocin is essential for maintaining the health and safety of mother and child. It is a neuromodulator in the central nervous and periphery through endocrine and paracrine pathways.
Hence as per the factors above, the Antepartum segment will likely face growth over the forecast period.
Moreover, the number of live births and pregnancy complications in Mexico and Canada regions are also fuelling factors for the market growth. For instance, as per the “National Vital Statistics Reports” published in February 2022, the percentages of unmarried births ranged from about one in five births in Utah (19.3%) to more than one in two births in Louisiana (54.5%), Mississippi (55.8%), and New Mexico (53.2%) in 2020. Hence varied birth populations in the different regions of North America are anticipated to boost the market growth over the forecast period.
Furthermore, the government initiative to provide more information and awareness to people regarding the use of Oxytocin fuels the market growth. For instance, the 2021 report from SafeMedicationUse.ca with the support of Health Canada released a handout titled “Oxytocin to Start or Advance Labour: 5 Questions to Ask”, which describes the benefits and risks of oxytocin and was able to help pregnant individuals and their support person have conversations with their health care team. Hence people are likely to get familiar with the usage of Oxytocin and thus boosting the market growth.
As per the factors mentioned above, North America is expected to witness growth over the forecast period.
This product will be delivered within 2 business days.
COVID-19 significantly impacted the oxytocin market and the overall healthcare industry during the initial phase. For instance, as per the article published in May 2022 under the title "Oxytocin, the Panacea for Long-COVID? A Review", in the study," researchers evaluated the underlying mechanisms for long-COVID and how the oxytocinergic neurons are likely to be affected by SARS-CoV-2 leading to a reduction in plasma oxytocin (OXT). The study also identified a potential mechanism for long-COVID that involves OXT dysfunction. Furthermore, the article published in August 2021 titled" Covid and Oxytocin: Looking for Microbial Symbiosis” stated that the oxytocin hormone has anti-inflammatory and antioxidant protective effects and has received particular attention due to the pandemic of COVID-19. Hence, as per the factors mentioned above, COVID-19 significantly impacted the oxytocin market.
Factors driving the market growth include the increasing prevalence of pregnancy complications, rising births globally, and growing awareness of induced labor and breastfeeding. For instance, as per the December 2021 update from United Nations International Children's Emergency Fund (UNICEF), an estimated 140 million children were born in 2021. Furthermore, as per the August 2021 update from International Institute for Sustainable Development, the global population is projected to increase to 9.7 billion by 2050. This level represents a nearly 24% increase over 2020. Because of the increased birth rate and population levels, there is a high chance for growth of the oxytocin market since oxytocin is advised for antepartum and postpartum pregnancy.
Moreover, the presence of competitors, new developments associated with oxytocin, and collaborations boost the market growth. For instance, per the January 2021 update, Tonix Pharmaceuticals entered a licensing agreement with Katana Pharmaceuticals for its intranasal potentiated oxytocin to expand its use in metabolic disorders, especially insulin resistance, diabetes, and obesity. The licensing deal is an addition to the company's original purchase of oxytocin-potentiated therapy from Trigemina in June 2020, with preclinical data demonstrating the efficacy of the intranasal oxytocin product TNX-1900 in disorders of the central nervous system, with migraine chosen as the lead indication by Tonix. These oxytocin-related collaborative ventures and partnerships open the way for various indications, supporting the market's growth over the forecast period.
Furthermore, the application of oxytocin in pregnancy boosts the market growth, for instance, as per the article published in July 2020 titled "Role of Oxytocin in Prevention of Postpartum Hemorrhage in Unplanned Out-of-Hospital Deliveries Treated By Emergency Medical Services" in Finland, postpartum hemorrhage following unplanned out-of-hospital deliveries was prevented by intramuscular or intravenous oxytocin administration. Rising disposable incomes, especially in developing countries, increasing awareness regarding pregnancy care products among women, an increase in the literacy rate of women, and an increase in well-developed distribution channels for oxytocin products are the major factors driving the growth of the oxytocin market.
As per the factors above, the oxytocin market will likely grow over the forecast period. However, stringent regulations and the high cost of oxytocin drugs associated with the drug restrain the market growth.
Oxytocin Market Trends
Antepartum Segment is Expected to Witness Growth Over the Forecast Period
Antepartum oxytocin injection (synthetic) is indicated for initiating or improving uterine contractions, where it is desirable and considered suitable to achieve early vaginal delivery for fetal or maternal reasons. In the antepartum period, exogenous oxytocin is the United States Food and Drug Administration (FDA) approved for strengthening uterine contractions with the aim of successful vaginal delivery of the fetus.Research and development, product launches, mergers, and acquisitions in the studied segment boost the market growth. For instance, as per the article published in May 2020 under the title “Augmentation of Labor With Oxytocin and its Association With Delivery Outcomes: A Large-Scale Cohort Study in 12 Public Hospitals in Nepal”, the augmentation of labor with oxytocin was associated with beneficial effects, such as improved monitoring and a decreased risk of cesarean section. Proper use of oxytocin was needed to augment labor in low-resource contexts and call for evidence-based guidelines on the augmentation of labor in low-resource settings.
Moreover, according to the article titled “The Role of Oxytocin and the Effect of Stress During Childbirth: Neurobiological Basics and Implications for Mother and Child,” published in October 2021 stated that, during pregnancy, childbirth, and beyond, the neuropeptide oxytocin is essential for maintaining the health and safety of mother and child. It is a neuromodulator in the central nervous and periphery through endocrine and paracrine pathways.
Hence as per the factors above, the Antepartum segment will likely face growth over the forecast period.
North America is Expected to Dominate the Oxytocin Market
North America dominates the oxytocin products market, due to the increasing number of preterm births, fertility rates, and increasing healthcare expenditure. For instance, according to the Centers for Disease Control and Prevention (CDC), “Births: Provisional Data for 2021” report, the number of births in the United States and the general fertility rate increased for the first time in seven years in 2021. The report shows a 1% increase in births from 2020, with 3,659,289 births recorded in 2021. As per the same source, the preterm birth rate rose 4% in 2021 to 10.48%, from 10.09% in 2020. During antepartum oxytocin helps in strengthening uterine contractions with the aim of successful vaginal delivery of the fetus. Since oxytocin is indicated and approved in both the antepartum and postpartum period the market is likely to grow due to the increase in the number of births in the studied region.Moreover, the number of live births and pregnancy complications in Mexico and Canada regions are also fuelling factors for the market growth. For instance, as per the “National Vital Statistics Reports” published in February 2022, the percentages of unmarried births ranged from about one in five births in Utah (19.3%) to more than one in two births in Louisiana (54.5%), Mississippi (55.8%), and New Mexico (53.2%) in 2020. Hence varied birth populations in the different regions of North America are anticipated to boost the market growth over the forecast period.
Furthermore, the government initiative to provide more information and awareness to people regarding the use of Oxytocin fuels the market growth. For instance, the 2021 report from SafeMedicationUse.ca with the support of Health Canada released a handout titled “Oxytocin to Start or Advance Labour: 5 Questions to Ask”, which describes the benefits and risks of oxytocin and was able to help pregnant individuals and their support person have conversations with their health care team. Hence people are likely to get familiar with the usage of Oxytocin and thus boosting the market growth.
As per the factors mentioned above, North America is expected to witness growth over the forecast period.
Oxytocin Industry Overview
The oxytocin market is competitive and consists of a few major players. The competitive landscape includes an analysis of a few international and local companies. Many of these companies are undertaking various strategies to maintain their market shares, such as mergers, acquisitions, collaborations, product launches, etc. Companies like Bimeda, GlaxoSmithKline PLC, Grindeks, JHP Pharmaceuticals, KAPL, Novartis AG, Pfizer Inc., and Shanghai Hefeng hold a substantial share in the market.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AdvaCare Pharma
- Fresenius Kabi AG
- Wockhardt Ltd
- JHP Pharmaceuticals
- Karnataka Antibiotics and Pharmaceuticals Limited (KAPL)
- Weefsel Pharma
- Pfizer Inc.
- EVER Pharma
- Par Pharmaceutical.
- Viatris Inc. (Mylan)
- Hikma Pharmaceuticals PLC
Methodology
LOADING...
